Last reviewed · How we verify
MultiHance 0.05 mmol/kg
MultiHance is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues.
MultiHance is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues. Used for Contrast-enhanced MRI of the brain, spine, and associated tissues, Contrast-enhanced MRI of the liver, Contrast-enhanced MRI of the body (general use).
At a glance
| Generic name | MultiHance 0.05 mmol/kg |
|---|---|
| Sponsor | Bracco Diagnostics, Inc |
| Drug class | Gadolinium-based contrast agent |
| Target | Water proton relaxation (T1 relaxation enhancement) |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
MultiHance contains gadobenate dimeglumine, a paramagnetic gadolinium chelate that distributes into the extracellular space and is taken up by hepatocytes. By altering local magnetic field homogeneity, it increases signal intensity in T1-weighted MRI images, improving visualization of tissue perfusion and lesion characterization. The agent is eliminated renally and hepatically.
Approved indications
- MRI contrast enhancement for central nervous system imaging
- MRI contrast enhancement for body imaging including liver lesion characterization
Common side effects
- Gadolinium retention in tissues
- Nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment
- Injection site reactions
- Headache
- Nausea
Key clinical trials
- P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) (PHASE2)
- Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients
- Crossover Comparison of MultiHance and Dotarem (PHASE4)
- Contrast-enhanced MRI in Children 2 Months to <2 Years (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MultiHance 0.05 mmol/kg CI brief — competitive landscape report
- MultiHance 0.05 mmol/kg updates RSS · CI watch RSS
- Bracco Diagnostics, Inc portfolio CI